metastatic prostate cancer

Ask MedXY AI

Latest news

Tag

newsmetastatic prostate cancerPARP inhibitors

Underutilization of PARP Inhibitors in Metastatic Prostate Cancer With BRCA1/2 Alterations: Insights from a US Real-World Cohort

By MedXY|Oct 4, 2025

Despite proven survival benefit, nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations did not receive PARP inhibitors in a US real-world study, highlighting critical gaps in treatment ac

Clinical Updatesmetastatic prostate cancerPSMA

First-in-Human Results of Terbium-161 PSMA Radioligand Therapy in mCRPC: Insights from the VIOLET Study

By MedXY|Oct 1, 2025

A phase 1/2 trial demonstrates the safety of [161Tb]Tb-PSMA-I&T, a novel dual beta-Auger radioligand, in heavily pretreated metastatic castration-resistant prostate cancer patients, supporting further clinical investigation.